At a glance
A GLP-1 receptor agonist studied in glucose regulation and weight management.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Clinical findings relate to defined products, indications and populations. Research-vial arithmetic does not establish equivalence with approved oral or injectable medicines.[1][2][1]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Semaglutide.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Titration (2 mL = ~2.5 mg/mL)
| Week | Weekly Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) | 10 units (0.10 mL) |
| Weeks 5–8 | 500 mcg (0.5 mg) | 20 units (0.20 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 40 units (0.40 mL) |
| Weeks 13–16 | 1700 mcg (1.7 mg) | 68 units (0.68 mL) |
| Weeks 17+ (Maintenance) | 2400 mcg (2.4 mg) | 96 units (0.96 mL) |
Frequency: Inject once weekly subcutaneously. This gradual titration protocol improves tolerability and is consistent with FDA-approved dosing strategies for weight management[1][2]. Administer on the same day each week at any time, with or without meals. Note: We use 2.0 mL reconstitution (instead of 3.0 mL) to keep the highest maintenance dose under 1.0 mL per injection.
Additional schedule context & duration
Concise summary of the once-weekly regimen.
- Goal: Support chronic weight management through GLP-1 receptor activation, leading to reduced appetite and improved metabolic parameters[1].
- Schedule: Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation.
- Dose Range: 250 mcg (0.25 mg) to 2400 mcg (2.4 mg) weekly with stepwise titration every 4 weeks to improve tolerability.
- Reconstitution: 2.0 mL per 5 mg vial (~2.5 mg/mL) for accurate unit measurements on standard insulin syringes.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 28 days; avoid repeated freeze–thaw cycles.
Suggested weekly titration approach based on clinical approval and studies[1][2].
- Weeks 1–4: 250 mcg (0.25 mg) once weekly to establish baseline tolerance.
- Weeks 5–8: 500 mcg (0.5 mg) once weekly.
- Weeks 9–12: 1000 mcg (1.0 mg) once weekly.
- Weeks 13–16: 1700 mcg (1.7 mg) once weekly.
- Weeks 17+ (Maintenance): 2400 mcg (2.4 mg) once weekly as target maintenance dose.
- Frequency: Once per week (subcutaneous injection).
- Timing: Administer on the same day each week at any time; rotate injection sites to reduce local irritation.
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to minimize foaming; avoid shaking.
- Gently swirl or roll the vial until the powder is fully dissolved.
- Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use reconstituted solution within 28 days for maximum potency and safety[6].
Storage Instructions
Storage requirements are formulation-specific. Peptide stability depends on sequence, concentration, pH, buffer, excipients, surfaces, agitation, temperature, and lyophilization conditions[5].
- Research preparations: Use validated stability data supplied for the exact formulation rather than applying a universal storage period.
- Handling records: Document preparation date, storage temperature, light exposure, sterility controls, and any temperature excursion.
- Finished approved products: Follow the product-specific prescribing information. Storage instructions for a finished semaglutide injection should not be transferred to a separately reconstituted research vial.
Injection Technique
General subcutaneous injection guidance from clinical best-practice resources[8][9][10].
- Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely before proceeding[9].
- Pinch a fold of skin between your fingers; insert the needle at a 45–90° angle into the subcutaneous tissue (fatty layer, not muscle)[8][10].
- Do not aspirate (pull back the plunger) when giving a subcutaneous injection[8].
- Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle to ensure complete delivery and minimize leakage.
- Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
- Rotate injection sites systematically (abdomen, thighs, upper arms) with each weekly injection to prevent lipohypertrophy and maintain consistent absorption[9]. The abdomen is the preferred site for most consistent absorption.
- Dispose of used syringes and needles immediately in a proper FDA-approved sharps container[10].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–20 week weekly titration protocol.
- Peptide Vials (Semaglutide, 5 mg each):
- 8 weeks ≈ 1 vial (3 mg total used)
- 12 weeks ≈ 2 vials (7 mg total used)
- 16 weeks ≈ 3 vials (13.8 mg total used)
- 20 weeks ≈ 5 vials (23.4 mg total used with maintenance dosing)
- Insulin Syringes (U-100):
- Per week: 1 syringe
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
- 20 weeks: 20 syringes
- Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 2 mL → 1 × 10 mL bottle
- 12 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- 16 weeks (3 vials): 6 mL → 1 × 10 mL bottle
- 20 weeks (5 vials): 10 mL → 1 × 10 mL bottle
Note: Use bacteriostatic water within 28 days after opening[7].
- Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs
- 12 weeks: 24 swabs
- 16 weeks: 32 swabs
- 20 weeks: 40 swabs → recommend 1 × 100-count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
PMC – Once-Weekly Semaglutide for Weight Management: A Clinical Review — Comprehensive review of Semaglutide’s mechanism, efficacy, and safety in weight management (clinical data, half-life, GLP-1 receptor activation, weekly dosing) (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Continue exploring
Related topics are not interchangeable compounds or formulations.